Source: Clinical Trials Arena

Beckley Psytech: Beckley Psytech completes subjects' enrolment for Phase IIb trial of TRD therapy

Beckley Psytech has completed subject enrolment for the core stage of Phase IIb trial of patent-protected BPL-003 for individuals with TRD. The post Beckley Psytech completes subjects' enrolment for Phase IIb trial of TRD therapy appeared first on Clinical Trials Arena.

Read full article »

Beckley Psytech's Competitors | Beckley Psytech's News | Beckley Psytech's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-Founder & CEO

Cosmo Feilding Mellen

CEO Approval Rating

90/100

Beckley Psytech is an England-based biopharmaceutical company that researches and develops psychedelic medicines for the treatment of neurological and psychiatric disorders.